SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated benchtop DNA and mRNA synthesis solutions, today announced a focus in strategy enabled by the commercial availability of its groundbreaking Gibson SOLA platform. Going forward, the company will increasingly concentrate its efforts on expanding the adoption of Gibson SOLA for both DNA and mRNA high throughput drug discovery applications and will specifically target the BioXp automation platform on mRNA synthesis, where the Company believes it has a highly differentiated offering with significant advantages over existing solutions.

圣迭戈，2024年4月18日（环球通讯社）--自动化台式DNA和mRNA合成解决方案的领导者Telesis Bio Inc.（纳斯达克：TBIO）今天宣布，其开创性的Gibson SOLA平台的商业可用性使战略重点成为可能。展望未来，该公司将越来越专注于扩大Gibson SOLA在DNA和mRNA高通量药物发现应用中的应用，并将专门针对mRNA合成的BioXp自动化平台，该公司认为它具有高度差异化的产品，与现有解决方案相比具有显着优势。

The Company believes that its Gibson SOLA platform, an industry leading EDS solution, is easily integrated onto many third-party automation platforms as well as the Company’s own BioXp system, and enables the synthesis of high-fidelity synthetic oligonucleotides, genes, and transfection-ready mRNA at a wide range of scales as quickly as overnight.

该公司认为，其Gibson SOLA平台（一种业界领先的EDS解决方案）可以轻松集成到许多第三方自动化平台以及公司自己的BioXp系统中，并能够在一夜之间快速合成高保真合成寡核苷酸，基因和转染就绪的mRNA。

This accelerated synthesis capability allows researchers to identify, screen and optimize complex constructs in as little as 2 days with more consistent and reliable results and much greater control. “We believe our advances in enzymatic synthesis will ultimately accelerate the current drug discovery paradigm by creating mRNA-based vaccine and therapeutic candidates in days rather than weeks or months,” said Dan Gibson, PhD, Co-Founder of Telesis Bio.

这种加速的合成能力使研究人员能够在短短的2天内识别，筛选和优化复杂的构建体，从而获得更一致和可靠的结果以及更大的控制。Telesis Bio联合创始人丹·吉布森（DanGibson）博士说：“我们相信，我们在酶促合成方面的进步最终将通过在几天而不是几周或几个月内创建基于mRNA的疫苗和候选治疗药物来加速当前的药物发现范式。”。

Gibson continued “we believe our collaborations continue to validate the technology’s potential to rapidly identify new vaccine and therapeutic candidates and provide both substantial technical and commercial validation of the Gibson SOLA approach, and the potential for significant future development and commercial milestone payments.” To solidify its p.

吉布森继续说道：“我们相信我们的合作将继续验证该技术快速识别新疫苗和治疗候选药物的潜力，并为吉布森SOLA方法提供实质性的技术和商业验证，以及未来重大开发和商业里程碑付款的潜力。”巩固其p。